[go: up one dir, main page]

WO2004045535A3 - Interactions moleculaires dans des neurones - Google Patents

Interactions moleculaires dans des neurones Download PDF

Info

Publication number
WO2004045535A3
WO2004045535A3 PCT/US2003/036698 US0336698W WO2004045535A3 WO 2004045535 A3 WO2004045535 A3 WO 2004045535A3 US 0336698 W US0336698 W US 0336698W WO 2004045535 A3 WO2004045535 A3 WO 2004045535A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
neurons
molecular interactions
pdz
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036698
Other languages
English (en)
Other versions
WO2004045535A2 (fr
Inventor
Peter S Lu
Jonathan David Garman
Michael P Belmares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbor Vita Corp
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Priority to EP03768964A priority Critical patent/EP1578365A4/fr
Priority to AU2003291558A priority patent/AU2003291558B2/en
Priority to CA002505479A priority patent/CA2505479A1/fr
Publication of WO2004045535A2 publication Critical patent/WO2004045535A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004045535A3 publication Critical patent/WO2004045535A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs perturbant la liaison entre une protéine PDZ et des ligands associés, notamment des récepteurs de N-méthyle-D-aspartate, impliqués dans des troubles neurologiques variés. L'invention concerne des compositions pharmaceutiques contenant ces inhibiteurs, et leur utilisation dans le traitement de maladies neurologiques, notamment l'accident vasculaire cérébral et l'ischémie. L'invention concerne des méthodes de criblage permettant d'identifier des inhibiteurs supplémentaires d'interactions de ligands protéiniques spécifiques avec des protéines PDZ.
PCT/US2003/036698 2001-08-03 2003-11-14 Interactions moleculaires dans des neurones Ceased WO2004045535A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03768964A EP1578365A4 (fr) 2002-11-14 2003-11-14 Interactions moleculaires dans des neurones
AU2003291558A AU2003291558B2 (en) 2001-08-03 2003-11-14 Molecular interactions in neurons
CA002505479A CA2505479A1 (fr) 2002-11-14 2003-11-14 Interactions moleculaires dans des neurones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42621302P 2002-11-14 2002-11-14
US42621202P 2002-11-14 2002-11-14
US60/426,213 2002-11-14
US60/426,212 2002-11-14

Publications (2)

Publication Number Publication Date
WO2004045535A2 WO2004045535A2 (fr) 2004-06-03
WO2004045535A3 true WO2004045535A3 (fr) 2006-07-13

Family

ID=32329101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036698 Ceased WO2004045535A2 (fr) 2001-08-03 2003-11-14 Interactions moleculaires dans des neurones

Country Status (3)

Country Link
EP (1) EP1578365A4 (fr)
CA (1) CA2505479A1 (fr)
WO (1) WO2004045535A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells
US11331364B2 (en) 2014-06-26 2022-05-17 Xigen Inflammation Ltd. Use for JNK inhibitor molecules for treatment of various diseases

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005061548A1 (fr) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides pour la modulation de la liaison des proteines du canal de recepteur de potentiel transitoire et proteines associees au recepteur de potentiel transitoire
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2613012A1 (fr) * 2005-06-23 2007-01-04 Arbor Vita Corporation Procedes et compositions de modulation de la cox
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP2043671B1 (fr) * 2006-07-11 2020-05-20 NoNO Inc. Peptide et composition de celui-ci pour son utilisation dans le traitement d'un accident cérébro-vasculaire accompagné de fièvre
EP1884521A1 (fr) * 2006-07-31 2008-02-06 Xigen S.A. Peptide de fusion pour inhiber l'interaction du récepteur neuronal NMDA (NMDAR) avec les protéines interagissant avec le récepteur NMDA
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
PL2440230T3 (pl) * 2009-06-10 2021-06-14 Nono Inc. Schematy leczenia do leczenia choroby neurologicznej
CA3018494C (fr) * 2009-06-10 2021-12-07 Nono Inc. Co-administration d'un agent lie a un peptide d'internalisation avec un anti-inflammatoire
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP2581384A1 (fr) * 2011-10-11 2013-04-17 Institut Pasteur Produits utiles pour le traitement des tumeurs malignes du système nerveux humain
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
CN106554386A (zh) * 2015-09-25 2017-04-05 广州恒上医药技术有限公司 人乳头瘤病毒的表位肽及其应用
AU2018383669B2 (en) 2017-12-13 2023-05-18 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
EP3762028A4 (fr) * 2018-03-08 2021-12-15 Phanes Therapeutics, Inc. Anticorps anti-tip-1 et utilisations associées
CN114807142B (zh) * 2022-05-26 2024-03-29 源生生物科技(青岛)有限责任公司 一种环状RNA-circ-Magi1及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273622C (fr) * 1999-06-02 2012-03-20 Michael Tymianski Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales
AU2001277986A1 (en) * 2000-07-25 2002-02-05 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
CA2434643C (fr) * 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides destines a l'activation et a l'inhibition de.delta.pkc
JP3536039B2 (ja) * 2001-05-08 2004-06-07 独立行政法人 科学技術振興機構 Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ
EP1443951A4 (fr) * 2001-08-03 2006-05-03 Arbor Vita Corp Interactions moleculaires dans les cellules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAFFREY ET AL.: "CAPON: A Protein Associated with Neuronal Nitric Oxide Synthase that Regulates Its Interactions with PSD-95", NEURON, vol. 20, January 1998 (1998-01-01), pages 115 - 124, XP002104610 *
KOMAU H.C. ET AL.: "Domain interactions between NMDA receptor subunits and the postsynaptic density protein, PSD-95", SCIENCE, vol. 269, 22 September 1995 (1995-09-22), pages 1737 - 1740, XP002196675 *
SCHWARZE ET AL.: "In vivo Protein Transduction: Delivery of Biologically active protein into the mouse", SCIENCE, vol. 285, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133 *
See also references of EP1578365A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells
US11331364B2 (en) 2014-06-26 2022-05-17 Xigen Inflammation Ltd. Use for JNK inhibitor molecules for treatment of various diseases

Also Published As

Publication number Publication date
CA2505479A1 (fr) 2004-06-03
EP1578365A4 (fr) 2009-09-23
EP1578365A2 (fr) 2005-09-28
WO2004045535A2 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004045535A3 (fr) Interactions moleculaires dans des neurones
WO2004005934A3 (fr) Marqueurs de toxicite
WO2005035551A3 (fr) Inhibiteurs de proteines se liant a des molecules phosphorylees
EP2993187A3 (fr) Anticorps dirigés contre her-3 et leurs utilisations
WO2004087887A3 (fr) Complexes intracellulaires utilises comme biomarqueurs
AU2001257012A1 (en) Methods for selective targeting
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
EP2537524A3 (fr) Traitement de maladies induites par les lymphocytes T
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
IL197721A (en) An isolated monoclonal antibody associated with Delta-Lake 4 (dll4), its pharmacological preparations, polynucleotides encoding them and their use in the manufacture of cancer drugs
EP2399936A3 (fr) Anticorps anti-CD154
WO2002002638A3 (fr) Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble
IL186671A (en) Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs
EP2371390A3 (fr) Antagonistes et leurs procédés d'utilisation
WO2006073941A3 (fr) Polypeptides de liaison a la br3 et leurs utilisations
WO2003043583A3 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
EP2366715A3 (fr) Molécules chimère d'anticorps anti-RANKL et de PTH/PTHRP
EP1983002A3 (fr) Sites de phosphorylation à tyrosine et anticorps spécifiques
WO2003070892A3 (fr) Inhibiteurs des proteines rgs
WO2008113515A3 (fr) Antagonistes sélectifs de hutnfr1
EP2402372A3 (fr) Agent thérapeutique
WO2020057540A8 (fr) Anticorps anti-cxcl13 pour le traitement de maladies auto-immunes et du cancer
EP1983003A3 (fr) Sites de phosphorylation à tyrosine et anticorps spécifiques
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2007014170A3 (fr) Compositions et methodes de desagregation des proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2505479

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003291558

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003768964

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003768964

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP